Asset Details
Do you wish to reserve the book?
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
Do you wish to request the book?
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
2021
Overview
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Antibodies, Neutralizing - immunology
/ Antibodies, Viral - immunology
/ COVID-19
/ COVID-19 - prevention & control
/ COVID-19 Vaccines - immunology
/ Humans
/ Medicine and Health Sciences
/ Proteins
/ Rabies
/ Research and Analysis Methods
/ Severe acute respiratory syndrome
/ Severe acute respiratory syndrome coronavirus 2
/ Vaccines
/ Viruses
